Zobrazeno 1 - 10
of 411
pro vyhledávání: '"Michael von Bergwelt"'
Autor:
Nabeel Mansour, Kathrin Heinrich, Danmei Zhang, Michael Winkelmann, Maria Ingenerf, Lukas Gold, Konstantin Klambauer, Martina Rudelius, Frederick Klauschen, Michael von Bergwelt-Baildon, Jens Ricke, Volker Heinemann, C. Benedikt Westphalen, Wolfgang G. Kunz
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Purpose To assess the eligibility of patients with advanced or recurrent solid malignancies presented to a molecular tumor board (MTB) at a large precision oncology center for inclusion in trials with the endpoints objective response rate (O
Externí odkaz:
https://doaj.org/article/47042810f04d489eba1c81669198440c
Autor:
Julia Kasprzak, Timothy Goering, Karin Berger-Thürmel, Vanessa Kratzer, Wuthichai Prompinit, Sven P. Wichert, Simon Leutner, Norbert Langermann, Michael von Bergwelt-Baildon, Volker Heinemann, Hana Algül, Martin Zünkeler, Daniel Nasseh
Publikováno v:
Digital Health, Vol 10 (2024)
Objectives The treatment of rare tumors often necessitates the involvement of highly specialized teams, typically based in larger medical centers or university hospitals, which are often lacking in rural areas. The German TARGET (the Trans-sectoral P
Externí odkaz:
https://doaj.org/article/8edf269f97ab4f56acc84ddeb931d70b
Autor:
Krasimira Aleksandrova, Jana Leise, Christoph Priesner, Murat Aktas, Michael Apel, Mario Assenmacher, Iris Bürger, Anne Richter, Pia Altefrohne, Christine Schubert, Astrid Holzinger, Markus Barden, Valerie Bezler, Michael von Bergwelt-Baildon, Peter Borchmann, Lilia Goudeva, Wolfgang Glienke, Lubomir Arseniev, Ruth Esser, Hinrich Abken, Ulrike Koehl
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionPoint-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade. In addition to the use of CD19 CAR T cells for hematological diseases, there is a growing interest in targetin
Externí odkaz:
https://doaj.org/article/f6589c518506495e91a9217ebb7da6b4
Autor:
Alexander Quaas, Julie George, Philipp Müller, Hans Anton Schlößer, Michael von Bergwelt-Baildon, Martin Thelen, Birgit Gathof, Martin Peifer, Thomas Zander, Axel M Hillmer, Christiane Bruns, Diandra Keller, Jonas Lehmann, Kerstin Wennhold, Eugen Bauer, Maria Alejandra Garcia-Marquez, Roman Thomas, Lukas Maas, Miloš Nikolić, Wolfgang Schröder, Ali M Yazbeck
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background The individual HLA-I genotype is associated with cancer, autoimmune diseases and infections. This study elucidates the role of germline homozygosity or allelic imbalance of HLA-I loci in esophago-gastric adenocarcinoma (EGA) and determines
Externí odkaz:
https://doaj.org/article/afc5d656bb5b494e9b31c5d4b6a0c547
Autor:
Anastasia Tsakmaklis, Fedja Farowski, Rafael Zenner, Till Robin Lesker, Till Strowig, Hans Schlößer, Jonas Lehmann, Michael von Bergwelt-Baildon, Cornelia Mauch, Max Schlaak, Jana Knuever, Viola Schweinsberg, Lucie M. Heinzerling, Maria J. G. T. Vehreschild
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Composition of the intestinal microbiota has been correlated to therapeutic efficacy of immune checkpoint inhibitors (ICI) in various cancer entities including melanoma. Prediction of the outcome of such therapy, however, is still
Externí odkaz:
https://doaj.org/article/69ad8fc3b2f647bf81cbb0789a13962b
Autor:
Nabeel Mansour, Kathrin Heinrich, Danmei Zhang, Michael Winkelmann, Maria Ingenerf, Lukas Gold, Konstantin Klambauer, Martina Rudelius, Frederick Klauschen, Michael von Bergwelt-Baildon, Jens Ricke, Volker Heinemann, C. Benedikt Westphalen, Wolfgang G. Kunz
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/a22b6c35648c4250bc7b8c9caf5f9505
Autor:
Klara Dorman, Stefan Boeck, Robert J. Snijder, Jens T. Siveke, Michael Schenk, Julia Mayerle, Karel Caca, Jens Freiberg-Richter, Ludwig Fischer von Weikersthal, Frank Kullmann, Anke Reinacher-Schick, Martin Fuchs, Stephan Kanzler, Volker Kunzmann, Thomas J. Ettrich, Danmei Zhang, Swantje Held, Ayad Abdul-Ahad, Michael von Bergwelt-Baildon, Volker Heinemann, Michael Haas
Publikováno v:
Current Oncology, Vol 30, Iss 6, Pp 5828-5834 (2023)
This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the “Burden of Therapy” (BOTh®TM) in pancreatic ductal adenocarcinoma (PDAC). In the RASH study, 150 patients with newly diagnosed metastatic PDAC were trea
Externí odkaz:
https://doaj.org/article/d4ab867951864e49ad0edeb7b333eb01
Autor:
Sebastian Mönch, Maurice M. Heimer, Michael Winkelmann, Anne Guertler, Max Schlaak, Amanda Tufman, Najib Ben Khaled, Enrico de Toni, Christoph B. Westphalen, Michael von Bergwelt-Baildon, Julien Dinkel, Philipp M. Kazmierczak, Michael Ingrisch, Nabeel Mansour, Marcus Unterrainer, Lucie Heinzerling, Jens Ricke, Wolfgang G. Kunz
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Pseudoprogression (PsPD) is a rare response pattern to immune checkpoint inhibitor (ICI) therapy in oncology. This study aims to reveal imaging features of PsPD, and their association to other relevant findings. Methods Patients w
Externí odkaz:
https://doaj.org/article/2c2fcfaf0c564e3e9f88c328dca83c52
Autor:
Michael Winkelmann, Viktoria Blumenberg, Kai Rejeski, Veit L. Bücklein, Maria Ingenerf, Marcus Unterrainer, Christian Schmidt, Franziska J. Dekorsy, Peter Bartenstein, Jens Ricke, Michael von Bergwelt-Baildon, Marion Subklewe, Wolfgang G. Kunz
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Chimeric antigen receptor T-cell therapy (CART) prolongs survival for patients with refractory or relapsed lymphoma. Discrepancies among different response criteria for lymphoma under CART were recently shown. Our objective was to
Externí odkaz:
https://doaj.org/article/73278b75b00246d0a561f64ef37870ed
Autor:
Christian Schmidt, Jens Ricke, Marion Subklewe, Veit Bücklein, Michael von Bergwelt-Baildon, Wolfgang G Kunz, Kai Rejeski, Viktoria Blumenberg, Michael Winkelmann, Christina Quell, Maria Ingenerf, Marcus Unterrainer, Franziska J Dekorsy, Peter Bartenstein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Chimeric antigen receptor T-cell therapy (CART) is effective for patients with refractory or relapsed lymphoma with prolongation of survival. We aimed to improve the prediction of Lugano criteria for overall survival (OS) at 30-day follow-
Externí odkaz:
https://doaj.org/article/0dadff192d194a0591398ea7549ee4a4